Utilization of the panel of 94 autoantibodies as a classifier in the non-invasive prenatal diagnostics of the Down Syndrome chromosome aberration based on in-blood analysis

摘要

the invention discloses the use of panel 94 autoantibodies as a complete klasyfikatora in nieinwazyjnej diagnosis prenatal down syndrome. determination of the expression panel of these autoantibodies in plasma / serum can be any method for determining protein, inter alia, based on antibodies against him namely.the elisa method chemiluminescencyjne, various types of mikromacierze protein and widely used in proteomice mass spectrometry. regardless of the method for determining the blood content of autoantibodies within the klasyfikatora may become in the future the early and, above all, it diagnosed foetal trisomii chromosome 21.